1. Home
  2. PECO vs EWTX Comparison

PECO vs EWTX Comparison

Compare PECO & EWTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Phillips Edison & Company Inc.

PECO

Phillips Edison & Company Inc.

N/A

Current Price

$40.43

Market Cap

5.2B

Sector

Real Estate

ML Signal

N/A

Logo Edgewise Therapeutics Inc.

EWTX

Edgewise Therapeutics Inc.

N/A

Current Price

$40.02

Market Cap

4.3B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
PECO
EWTX
Founded
1991
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.2B
4.3B
IPO Year
2010
2021

Fundamental Metrics

Financial Performance
Metric
PECO
EWTX
Price
$40.43
$40.02
Analyst Decision
Buy
Strong Buy
Analyst Count
14
13
Target Price
$43.46
★ $56.17
AVG Volume (30 Days)
968.8K
★ 1.4M
Earning Date
10-26-2026
11-04-2026
Dividend Yield
★ 3.42%
N/A
EPS Growth
★ 74.51
N/A
EPS
1.05
★ 8.86
Revenue
★ $726,594,000.00
N/A
Revenue This Year
$5.19
N/A
Revenue Next Year
$6.41
N/A
P/E Ratio
$38.48
★ $4.65
Revenue Growth
★ 9.86
N/A
52 Week Low
$34.49
$19.76
52 Week High
$44.38
$48.78

Technical Indicators

Market Signals
Indicator
PECO
EWTX
Relative Strength Index (RSI) 56.04 44.25
Support Level $38.78 $37.22
Resistance Level $40.49 $41.60
Average True Range (ATR) 0.69 3.20
MACD -0.07 -0.37
Stochastic Oscillator 42.91 26.45

Price Performance

Historical Comparison
PECO
EWTX

About PECO Phillips Edison & Company Inc.

Phillips Edison & Co Inc is a real estate investment trust. The company also operates a third-party investment management business providing property management and advisory services to four unconsolidated institutional joint ventures, in which it has a partial ownership interest, and one private fund. It invests in well-occupied, grocery-anchored neighborhood and community shopping centers. It holds an integrated in-house operating platform built on a market of expertise designed to optimize property value and consistently deliver a great shopping experience.

About EWTX Edgewise Therapeutics Inc.

Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is developing novel therapeutics for muscular dystrophies and serious cardiac conditions. The company's product candidates are Sevasemten, EDG-7500, EDG-003, and EDG-15400. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies, including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company's products are currently in different stages of their development, being developed to target key muscle proteins and modulators to address a broad array of muscle diseases.

Share on Social Networks: